We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lateral Flow Assay Detects Leprosy Immune Response

By LabMedica International staff writers
Posted on 22 May 2014
Print article
Image: Packard FluoroCount microtiter-plate reader adapted to read lateral flow strips (Photo courtesy of PerkinElmer).
Image: Packard FluoroCount microtiter-plate reader adapted to read lateral flow strips (Photo courtesy of PerkinElmer).
Image: The ESEQuant Lateral Flow Assay Reader (Photo courtesy of Qiagen).
Image: The ESEQuant Lateral Flow Assay Reader (Photo courtesy of Qiagen).
Field-applicable tests detecting asymptomatic Mycobacterium leprae infection or predicting progression to leprosy are urgently required to determine both cellular and humoral immunity.

Leprosy, a curable infectious disease caused by M. leprae that affects the skin and peripheral nerves, is one of the six diseases considered as a major threat in developing countries as continued transmission in endemic areas likely occurs from the large reservoir of individuals who are infected subclinically.

Infectious disease specialists at the Leiden University Medical Center (The Netherlands) with colleagues in Ethiopia recruited for their study human immunodeficiency virus (HIV)-negative, newly diagnosed untreated leprosy patients, and healthy endemic controls from October 2011 until November 2012. Leprosy was diagnosed based on clinical, bacteriological and histological observations and classified by a skin biopsy.

The combined diagnostic value of interferon (IFN)-γ induced protein 10 (IP-10), interleukin-10 (IL-10) and anti-Phenolic Glycolipid-I (PGL-I) antibodies was tested using M. leprae-stimulated blood of leprosy patients and endemic controls (EC). For reduction of the overall test-to-result time, the minimal whole blood assay time required to detect distinctive responses was investigated. To accommodate Lateral Flow Assays (LFAs) for field settings, dry-format LFAs for IP-10 and anti-PGL-I antibodies were developed allowing storage and shipment at ambient temperatures. Additionally, a multiplex LFA-format was applied for simultaneous detection of anti-PGL-I antibodies and IP-10. For improved sensitivity and quantitation, upconverting phosphor (UCP) reporter technology was applied in all LFAs.

After immunochromatography, LF strips are scanned in a Packard FluoroCount microtiter- plate reader (PerkinElmer; Waltham, MA, USA) adapted with an infrared laser. Upon IR excitation at 980 nm, UCP reporter particles emit green light detectable using a 550 nm band pass filter. For strip analysis in Ethiopia, a lightweight portable LF strip reader with UCP capability was used (UCP-Quant, an ESEQuant LFR reader custom adapted with IR diode; (QIAGEN Lake Constance GmbH; Stockach, Germany).

Single and multiplex UCP-LFAs correlated well with enzyme-linked immunosorbent assays (ELISAs) run in parallel. The performance of dry reagent assays and portable, lightweight UCP-LF strip readers indicated excellent field-robustness. Notably, detection of IP-10 levels in stimulated samples allowed a reduction of the whole blood assay time from 24 hours to six hours. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed significantly between patients and endemic controls, indicating the feasibility to identify M. leprae infection in endemic areas.

The authors concluded that dry-format UCP-LFAs are low-tech, robust assays allowing detection of relevant cytokines and antibodies in response to M. leprae in the field. The high levels of IP-10 and the required shorter whole blood assay time, render this cytokine useful to discriminate between leprosy patients and endemic controls. The study was published on May 8, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Leiden University Medical Center
PerkinElmer 
QIAGEN Lake Constance GmbH


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.